Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia

Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and efficacy of combined therapy with deferasirox (DFX, 20-30 mg/kg daily) and deferoxamine (DFO, 35-50 mg/kg on 3-7 da...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lal, Ashutosh, Porter, John, Sweeters, Nancy, Ng, Vivian, Evans, Patricia, Neumayr, Lynne, Kurio, Gregory, Harmatz, Paul, Vichinsky, Elliott
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3592978/
https://ncbi.nlm.nih.gov/pubmed/23151373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcmd.2012.10.006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller